Bernstein downgraded Intellia Therapeutics (NTLA) to Market Perform from Outperform with a price target of $14.50, up from $14. The firm cites the disclosure of a new Grade 4 liver injury that led the company to pause its Phase 3 trials for the downgrade. The company’s platform safety is “becoming too big a risk,” the analyst tells investors in a research note. Bernstein says Intellia “is now firmly on the ‘too hard’ camp.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target lowered to $24 from $26 at Barclays
- AMZN, BABA, NTLA, XYZ: Cathie Wood Loads Up on Intellia, Block, Amazon & Alibaba, Cuts Stake in Shopify and Other Growth Stocks
- Cathie Wood’s ARK Investment buys 750K shares of Intellia Therapeutics today
- Intellia Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
- Intellia Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo